MSB:ASE
MBLTY:OTCPK

Mesoblast Ltd.

Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. The company's cardiovascular and neurologic product pipeline is being developed in partnership with Teva Pharmaceutical Industries Ltd. Mesoblast Ltd's subsidiaries include Mesoblast Inc., Mesoblast International SA, Mesoblast Australia Pty Ltd and Mesoblast UK Ltd.

Expert Comments:

Kevin DeGeeter, Ladenburg Thalmann (6/30/15)
"We view Mesoblast Ltd.'s pipeline of autoimmune disease programs (rheumatoid arthritis, Crohn's disease and diabetic kidney disease) as an area of potential overlap and potential partnership. . .the company may seek additional partnerships to commercialize its orthopedic products and additional intravenous product indications. . .Mesoblast has signed an option agreement with Celgene Corp., providing a right of first negotiations on several inflammation pipeline programs."

Jason Kolbert, Maxim Group (6/9/15)
"Mesoblast Ltd. announced results from a Phase 2 trial in patients with diabetic nephropathy; the data showed that a single infusion of intravenously delivered allogeneic mesenchymal precursor cells, MPC-300-IV, was safe, reduced damaging inflammation and preserved or improved renal function at least for 24 weeks. This is quite significant, in our opinion. . .for the first time, we are seeing the potential to alter the natural course of the disease."

Kevin DeGeeter, Ladenburg Thalmann (6/4/15)
"On June 7, 2015, Mesoblast Ltd. will present 6-month data from a Phase 2 study of its mesenchymal precursor cells in treatment of diabetic kidney disease at the American Diabetes Association meeting. . .we encourage investors to revisit the company's story ahead of the upcoming data presentation and believe results could serve as a material catalyst of Mesoblast shares."

Henry McCusker, RegMed Investors (5/12/15)
"Mesoblast Ltd.'s publication of results in the May issue of the peer-reviewed journal PLOS One showed that its proprietary allogeneic mesenchymal precursor cells (MPCs) can reduce inflammation and reverse abnormal function of blood vessels, including the coronary arteries, in a previously published sheep model of rheumatoid arthritis. . .the authors concluded that MPCs show significant promise in modulating not only local disease activity in chronic inflammation such as a poly or mono-arthritis, but also the systemic sequelae of the condition."

Jason Kolbert, Maxim Group (4/13/15)
"Mesoblast Ltd. has announced that Celgene Corp. has invested in the company, taking a ~$45M equity stake in Mesoblast. . .this news should remind investors of the value that big pharma sees in the cell therapy space and in the industry leader, Mesoblast. . .the company's Protocol 275 study continues to show a clear and meaningful survival benefit among responding pediatric bone marrow transplant recipients."

Kevin DeGeeter, Ladenburg Thalmann (4/13/15)
"Mesoblast Ltd. announced a six-month option agreement with Celgene Corp. that, in our view, promises to solidify Mesoblast's leadership position in regenerative medicine and accelerate development of the company's inflammatory products pipeline. Importantly, the agreement includes an AU$58.5M nonrefundable and noncreditable equity investment that removes a potential balance sheet overhang and funds operations into H2/16. Consummating a license agreement could further strengthen the balance sheet."

More Expert Comments

Experts Commenting on This Company

Kevin DeGeeter, Director, Equity Research Analyst – Ladenburg Thalmann
Katherine Genis, Analyst – Edison Investment Research
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Jason Kolbert, Senior Analyst – Maxim Group
Henry McCusker – Regenerative Medicine Investors
Henry McCusker, Founder and Director of Research – Scimitar Equity
Alain Vertes, Managing Director – NxR Biotechnologies GmbH

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Mesoblast Ltd. Content